LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants

Om avsnittet

Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well.

Om avsnittet

Fler avsnitt

Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more

After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress

Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung

From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage

From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections

Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study

HCW 2026: BlossomHill IPO'd last month to tackle precision oncology, with a Scientific Founder / CEO who already has a hall of fame record in the space - Jean Cui walks us through her programs

HCW 2026: As it approaches a BLA filing for its viral immunotherapy in prostate cancer, Candel has published its pivotal phase 3 data in Lancet Oncology and presented extended data at AUA

HCW 2026: H.C. Wainwright & Co. Senior Biotech Analyst Andres Maldonado shares his take on the latest in oncology